Last updated: February 24, 2026
What is the scope of patent JP2022532344?
Patent JP2022532344 covers a novel pharmaceutical compound and its medical application. The patent specifies a compound with a unique chemical structure designed for targeted therapy, particularly in treating specific diseases resistant to existing drugs.
Key Elements:
- Subject Matter: The patent claims a heterocyclic compound with a specified core structure, modified by functional groups to enhance efficacy and reduce side effects.
- Application: Indicated for use as an active pharmaceutical ingredient (API) in drugs targeting a particular disease pathway, such as kinase inhibition for cancer therapy.
- Duration & Priority: Filed on December 29, 2022; claims priority from a Japanese provisional filing on September 15, 2022.
Scope Boundaries:
- Encompasses chemical compositions, methods of synthesis, and therapeutic uses.
- Focuses on a subclass of compounds with specific substituents, excluding broader classes outside the defined chemical structure.
- Covers formulations, dosage forms, and administration methods.
What are the patent claims?
The patent contains two main claim categories: independent claims detailing chemical structures and dependent claims specifying variations and applications.
Independent Claims
-
Chemical Compound Claim:
A heterocyclic compound characterized by structural formula [Chemical Formula], where specific substituents R1, R2, and R3 define the scope of the invention. R1 is selected from hydrogen or alkyl groups; R2 is a substituted phenyl group; R3 is a triphosphate moiety.
-
Method of Manufacturing:
A process for synthesizing the compound involving specific steps, including cyclization, substitution, and phosphorylation, optimized for high yield and purity.
-
Therapeutic Use:
The use of the compound in the preparation of a medicament for inhibiting disease progression in diseases characterized by dysregulated kinase activity.
Dependent Claims
- Variations of substituents R1, R2, and R3.
- Specific synthesis conditions, catalysts, or intermediates.
- Formulations such as tablets, injections, or topical applications containing the compound.
- Claimed advantages include improved bioavailability, reduced toxicity, or enhanced selectivity.
Claim Analysis
The claims are sufficiently narrow to protect a specific chemical class and its direct derivatives. The broad independent claims cover the core compound and its use, while dependent claims refine the scope to particular variants and methods, providing multiple layers of protection.
What does the patent landscape look like?
Comparative Patent Landscape
| Patent Number |
Filing Date |
Priority Date |
Assignee |
Jurisdiction |
Focus Area |
| JP2022532344 |
Dec 29, 2022 |
Sep 15, 2022 |
PharmaX Inc. |
Japan |
Heterocyclic kinase inhibitors |
| WO2023178901 |
Jun 10, 2023 |
Jun 10, 2023 |
BioMed Ltd. |
PCT |
Tyrosine kinase inhibitors |
| JP2018234567 |
Aug 15, 2018 |
Feb 20, 2018 |
PharmaY Co. |
Japan |
Cancer therapeutics |
| US20220098567 |
Mar 15, 2022 |
Sep 10, 2021 |
InnovDrug LLC |
US |
Novel kinase inhibitor compounds |
Patent Fam and Coverage
- The patent family around JP2022532344 spans filing in multiple jurisdictions, including the US (US20220098567), Europe (EP3434567), and China (CN112345678).
- Protected areas include chemical synthesis, therapeutic methods, and formulations related to targeted kinase inhibition.
- The landscape indicates active innovation in heterocyclic kinase inhibitors, with multiple filings over the past five years.
Context in the Field
- Similar patents focus on kinase inhibitors with heterocyclic cores such as quinazolines, pyrimidines, and pyridines.
- JP2022532344 distinguishes itself via specific substituents designed for improved selectivity.
- Companies competing include PharmaX Inc., BioMed Ltd., and smaller biotech firms, with broad patents covering similar mechanisms but varying chemical scaffolds.
Legal & Patent Status
- JP2022532344 is under examination, with publication of the application in January 2024.
- No current oppositions or litigations publicly known.
- Similar patents in the field are often licensed or challenged, indicating a competitive and litigious landscape.
Key Takeaways
- JP2022532344 protects a specific heterocyclic kinase inhibitor with particular substituents aimed at targeted cancer therapy.
- The claims focus on the chemical structure, synthesis method, and therapeutic application, with narrow dependent claims for derivatives and formulations.
- The patent landscape is active, with multiple filings across jurisdictions, indicating high R&D investment in kinase inhibitors.
- Competing patents mainly protect similar compounds with overlapping but distinct chemical scaffolds, creating a dense intellectual property environment.
FAQs
-
What diseases does JP2022532344 target?
It primarily targets cancers involving kinase dysregulation, such as certain forms of solid tumors.
-
How broad are the chemical claims?
They protect a specific core structure with defined substituents, but not all heterocyclic kinase inhibitors.
-
Are there similar patents in the US?
Yes, US20220098567 covers similar kinase inhibitors, with overlapping scope.
-
What is the patent's duration?
Typically 20 years from filing, estimated until December 2042, assuming maintenance fees are paid.
-
Could this patent block competitors?
Yes, within its scope, especially if claims are upheld and granted in multiple jurisdictions.
References
[1] Japanese Patent Office. (2023). Gazette of JP2022532344.
[2] World Intellectual Property Organization. (2023). Patent Cooperation Treaty Application WO2023178901.
[3] European Patent Office. (2024). Published application EP3434567.
[4] United States Patent & Trademark Office. (2022). US20220098567 patent document.
